NCT04699721

Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC

Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable Non-small Cell Lung Cancer

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Xiangya Hospital of Central South University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety and effect of neoadjuvant chemotherapy and immunotherapy combined with probiotics for early resectable NSCLC patients.

Conditions

• Non-small Cell Lung Cancer Stage II
• Non-small Cell Lung Cancer Stage ⅢA
• Non-small Cell Lung Cancer Stage IIIB

Interventions

Type	Name	Description
DRUG	nivolumab 4.5mg/kg+Paclitaxel (albumin-bound type) 260mg / m2+ Carboplatin AUC5	3 cycles of nivolumab+Paclitaxel (albumin-bound type)+ Carboplatin AUC5 (21 days/cycle); as well as BiFico (oral taking, 4 capsules/time, 2 times per day)

Timeline

• Start date: 2020-07-01
• Primary completion: 2027-09-01
• Completion: 2027-12-01
• First posted: 2021-01-07
• Last updated: 2024-11-22

Locations

1 site across 1 country: China